| 產品描述： | FH535 is an inhibitor of Wnt/β-catenin and PPAR, with anti-tumor activities. |
| 靶點： |
PPAR;β-catenin;Wnt/beta-catenin;PPAR |
| 體內研究： |
FH535 (25 mg/kg, i.p.) exhibits an anti-tumor effect on pancreatic cancer xenografts in mice. FH535 also represses angiogenesis in pancreatic cancer xenografts |
| 參考文獻： |
1. Handeli S, et al. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther. 2008 Mar;7(3):521-9. 2. Wu MY, et al. FH535 inhibited metastasis and growth of pancreatic cancer cells. Onco Targets Ther. 2015 Jul 6;8:1651-70.3. Liu L, et al. FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis. Oncotarget. 2016 Jul 26;7(30):47145-47162. |
| 溶解性： |
DMSO : 33.33 mg/mL (92.28 mM; Need ultrasonic) |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.769 ml |
13.843 ml |
27.685 ml |
| 5 mM |
0.554 ml |
2.769 ml |
5.537 ml |
| 10 mM |
0.277 ml |
1.384 ml |
2.769 ml |
| 50 mM |
0.055 ml |
0.277 ml |
0.554 ml |
|
| 注意： |
部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京